BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Chronic Heart Failure KOL Interview – Germany

August 15, 2022

This interview with a Germany-based key opinion leader (KOL) provides insights into patient segmentation, as well as prescribing trends for key marketed brands and late-phase pipeline therapies for chronic heart failure (CHF). Marketed brands discussed include Entresto, Farxiga, Jardiance, Corlanor, and Verquvo, while pipeline therapies highlighted are omecamtiv mecarbil, Zynquista, Invokana, Kerendia, Furoscix, and Revascor. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only)

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357. 

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Chronic Heart Failure - Preserved Ejection Fraction (Chronic HFpEF)
Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF)
Chronic Heart Failure and Cardiomyopathies - Unspecified

 Additional Resources:
Back to the top Back to the top